{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(23)"],"submitter":["Lee CJ"],"pubmed_abstract":["Clear cell sarcoma (CCSA) is characterized by a chromosomal translocation leading to <i>EWSR1</i> rearrangement, resulting in aberrant transcription of multiple genes, including <i>MET</i>. The EORTC 90101 phase II trial evaluated the MET inhibitor crizotinib in CCSA but resulted in only sporadic responses. We performed an in-depth histopathological and molecular analysis of archival CCSA samples to identify alterations potentially relevant for the treatment outcome. Immunohistochemical characterization of MET signaling was performed using a tissue microarray constructed from 32 CCSA cases. The DNA from 24 available tumor specimens was analyzed by low-coverage whole-genome sequencing and whole-exome sequencing for the detection of recurrent copy number alterations (CNAs) and mutations. A p"],"journal":["Cancers"],"pagination":["6057"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8657105"],"repository":["biostudies-literature"],"pubmed_title":["Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 \"CREATE\" Trial."],"pmcid":["PMC8657105"],"pubmed_authors":["Sciot R","Rutkowski P","Lambrechts D","Modave E","Stacchiotti S","Lee CJ","Schoffski P","Blay JY","Boeckx B","Debiec-Rychter M","Wozniak A"],"additional_accession":[]},"is_claimable":false,"name":"Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 \"CREATE\" Trial.","description":"Clear cell sarcoma (CCSA) is characterized by a chromosomal translocation leading to <i>EWSR1</i> rearrangement, resulting in aberrant transcription of multiple genes, including <i>MET</i>. The EORTC 90101 phase II trial evaluated the MET inhibitor crizotinib in CCSA but resulted in only sporadic responses. We performed an in-depth histopathological and molecular analysis of archival CCSA samples to identify alterations potentially relevant for the treatment outcome. Immunohistochemical characterization of MET signaling was performed using a tissue microarray constructed from 32 CCSA cases. The DNA from 24 available tumor specimens was analyzed by low-coverage whole-genome sequencing and whole-exome sequencing for the detection of recurrent copy number alterations (CNAs) and mutations. A p","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2026-06-19T03:21:32.095Z","creation":"2022-02-11T15:22:16.509Z"},"accession":"S-EPMC8657105","cross_references":{"pubmed":["34885165"],"doi":["10.3390/cancers13236057"]}}